Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL738612 | 0.81 | KDM4E (0.31) | — | |
| SCHEMBL738611 | 0.81 | KDM4E (0.31) | — | |
| SCHEMBL2760178 | 0.77 | CYP2D6 (0.37) | CYP2D6CYP2C19MMP1MMP8 | |
| SCHEMBL4898680 | 0.75 | CYP2D6 (0.35) | CYP2D6CYP2C19MMP1MMP8 | |
| SCHEMBL4898671 | 0.75 | CYP2D6 (0.35) | CYP2D6CYP2C19MMP1MMP8 | |
| SCHEMBL12778136 | 0.75 | CYP2D6 (0.35) | CYP2D6CYP2C19MMP1MMP8 | |
| SCHEMBL13887669 | 0.75 | — | — | |
| SCHEMBL8229231 | 0.75 | — | — | |
| SCHEMBL11100227 | 0.74 | ALDH1A1 (0.36) | CYP2D6CYP2C19MMP1MMP8 | |
| SCHEMBL13946654 | 0.74 | CYP2D6 (0.34) | CYP2D6CYP2C19MMP1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20220017566-A1 | TERPINOID DERIVATIVES AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC | 2022-01-20 | — | — | US | disclosed |
| WO-2021202720-A1 | USE OF TRITERPENOID NRF2 INHIBITORS | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2020068689-A1 | TERPINOID DERIVATIVES AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-04-02 | — | — | WO | disclosed |
| US-20160362478-A1 | CD4-MIMETIC SMALL MOLECULES SENSITIZE HUMAN IMMUNODEFICIENCY VIRUS TO VACCINE-ELICITED ANTIBODIES | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-12-15 | — | — | US | disclosed |
| US-9403763-B2 | CD4-mimetic inhibitors of HIV-1 entry and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-02 | — | — | US | disclosed |
| US-20140350113-A1 | CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350113-A1 | CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | CD4, CD14, CCR5 | CYP2D6 1986/4885CYP2C19 3337/4885MMP1 4562/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | CYP2D6 4714/4885CYP2C19 4869/4885MMP1 4279/4885 |
| US-20220017566-A1 | TERPINOID DERIVATIVES AND USES THEREOF | KEAP1, PTGES, GSTK1 | CYP2D6 2825/4885CYP2C19 2773/4885MMP1 3283/4885 |
| US-20160362478-A1 | CD4-MIMETIC SMALL MOLECULES SENSITIZE HUMAN IMMUNODEFICIENCY VIRUS TO VACCINE-ELICITED ANTIBODIES | CD4, CD14, CD81 | CYP2D6 4557/4885CYP2C19 4775/4885MMP1 4827/4885 |
| US-20230374035-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CYP2D6 3178/4885CYP2C19 3930/4885MMP1 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.